HC Wainwright Issues Pessimistic Outlook for Cibus Earnings

Cibus, Inc. (NASDAQ:CBUS – Free Report) – Research analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Cibus in a research report issued on Friday, November 13th. HC Wainwright analyst A. Dayal now expects that the company will earn ($1.18) per share for the year, down from their previous forecast of ($1.13). The consensus estimate for Cibus’ current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.28) EPS, FY2027 earnings at ($1.10) EPS, FY2028 earnings at ($1.12) EPS and FY2029 earnings at ($0.53) EPS.

Cibus (NASDAQ:CBUS – Get Free Report) last posted its earnings results on Thursday, November 12th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). Cibus had a negative net margin of 2,131.38% and a negative return on equity of 526.66%. The business had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.30 million.

Several other equities analysts have also issued reports on CBUS. Wall Street Zen lowered shares of Cibus from a “hold” rating to a “sell” rating in a report on Saturday, October 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Cibus presently has an average rating of “Hold” and a consensus price target of $9.00.

View Our Latest Stock Analysis on CBUS

Cibus Stock Down 1.4%

Shares of CBUS opened at $1.37 on Tuesday. The company has a 50 day moving average price of $1.42 and a 200-day moving average price of $1.81. Cibus has a fifty-two week low of $1.02 and a fifty-two week high of $4.19.

Institutional Investors Weigh In On Cibus

A number of institutional investors have recently added to or reduced their stakes in CBUS. Weiss Asset Management LP purchased a new position in Cibus in the first quarter valued at about $1,758,000. StoneX Group Inc. raised its holdings in Cibus by 115.9% in the third quarter. StoneX Group Inc. now owns 30,605 shares of the company’s stock worth $50,000 after purchasing an additional 16,430 shares in the last quarter. Nautilus Advisors LLC purchased a new stake in shares of Cibus during the third quarter valued at about $35,000. Rockland Trust Co. purchased a new stake in shares of Cibus during the second quarter valued at about $41,000. Finally, Bank of America Corp DE lifted its position in shares of Cibus by 324.2% during the first quarter. Bank of America Corp DE now owns 74,358 shares of the company’s stock valued at $147,000 after buying an additional 56,830 shares during the last quarter. Institutional investors own 33.81% of the company’s stock.

About Cibus

(Get Free Report)

Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA. The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.

Featured Articles

Earnings History and Estimates for Cibus (NASDAQ:CBUS)

Receive News & Ratings for Cibus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cibus and related companies with MarketBeat.com's FREE daily email newsletter.